Anaveon
Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.
Total raised
€136M
€135,662,977
Funding rounds
2
Investors
7
distinct backers
Active since
2018-12
latest 2021-12
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood39
base rate 48% for Series B
- ▼ Overdue vs cohort gap
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood20
base rate 12% (2+ rounds)
- ▲ €100M+ raised
- ▲ 9y since founding
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-12-16 | Series B | €106M | Cowen Healthcare Investments,Forbion Capital Partners,Novartis Venture Fund,Pfizer Ventures,Pontifax,Syncona Partners | View deal → |
| 2019-01-01 | Series A | €30M | Syncona Partners LLP | View deal → |
Investors
7Related news
- Anaveon raises CHF 110 millionstartupticker.ch · 2021-12
- startupticker.ch
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy